RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: Role of p53

International Journal of Cancer

Volumn 100, Issue 3, 2002, Pages 266-275

  Russo, Patrizia ^a   Malacarne, Davide ^a   Falugi, Carla ^b   Trombino, Sonya ^a   O'Connor, Patrick M ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 FU; Apoptosis; Cell cycle; Farnesyltransferase; p53

Indexed keywords

FLUOROURACIL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RAS PROTEIN; RPR 115135;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ALKYL AND ARYL TRANSFERASES; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; COLONIC NEOPLASMS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FLUOROURACIL; HUMANS; INDOLES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037143092     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10461     Document Type: Article

References (47)

1. Colorectal cancer
2. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
3. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group Study
4. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Anticancer Drug Screen and correlations with the growth inhibitory potency of 123 anticancer agents
5. Thymidine kinase, thymidylate Synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National cancer Institute's anticancer drug screen
6. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation
7. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia
8. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
9. New drugs in therapy of colorectal cancer: Preclinical studies
10. New directions in the treatment of colorectal cancer: A look to the future
11. Signal transduction from multiple Ras effectors
12. Blocking oncogenic Ras signaling for cancer therapy
13. Farnesyltransferase inhibitors, ras research yields a potential cancer therapeutic
14. Farnesyltransferase and geranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
15. Farnesyltransferase inhibitors. Potential role in the treatment of cancer
16. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
17. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas
18. Differential expression and mutation of the ras family genes in human breast cancer
19. Isotype-specific Ras. GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status
20. Farnesyltransferase inhibitors
21. Current status of clinical trials of farnesyltransferase inhibitors
22. Multivariate data analysis using D-optimal designs, partial least squares, and response surface modelling: A directional approach for the analysis of farnesyltransferase inhibitors
23. RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells
24. Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: Role of gene mutations
25. Nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-fluorouracil: Role of p53
26. c-myc down regulation induces apoptosis in human cancer cell lines exposed to RPR-115135, a non peptidomimetic farnesyltransferase inhibitor
27. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems
28. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors
29. Cell lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
30. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment
31. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors
32. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia
33. A gene hypermethylation profile of human cancer
34. INK4a/ARF-mutations accelerate lymphornagenesis and promote chemoresistance by disabling p53
35. p53: Only ARF the story
36. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
37. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol and gemcitabine
38. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
39. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
40. Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogens
41. Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species
42. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells
43. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines
44. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade
45. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A
46. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO-320-DM human colon tumour cells
47. The median-effect principle and the combination index for quantitation of synergism and antagonism